Skip to main content
Home
  • About Us
    • Our Credo
    • Board of Directors
      • Committees of the Board
    • Management Council
    • Sustainability
    • Manufacturing
    • Quality
    • Code of Conduct
    • Our History - Cipla Archives
    • Milestones and Awards
  • Our Presence
    • Australia
    • Brazil
    • Europe
    • Kenya
    • Malaysia
    • Morocco
    • Nepal
    • South Africa
    • Spain
    • Sri Lanka
    • Uganda
    • United Kingdom
    • USA
  • Our Offerings
    • Our Therapies
      • Respiratory
        • Asthma
        • Paediatric Asthma
        • COPD
        • Nebulization
      • HIV/AIDS
      • Oncology
      • Other Therapies
    • Cipla Generics
      • Products
        • Easylax
        • Easylax-L
    • OTC – Cipla Health
    • Cipla Diagnostics
    • API
  • Covid Care
  • Investors
    • Financials & Filings
      • Quarterly Results
      • Investor Presentation
      • Annual Reports
      • Scheme of Arrangement
    • Corporate Governance
    • Disclosure under regulation 46 of SEBI LODR
    • Cipla at a Glance
      • Board Of Directors
      • Committees of the Board
    • Investor Resources
    • Shareholding Pattern
    • Intimation to Stock Exchange
    • Unclaimed Data
    • Investor Contact
    • Disclaimer
  • Careers
    • Culture and Values
    • Life at Cipla
    • Job Search
  • Media Centre
    • Media Releases
    • In The News 
    • Leaders Speak
  • Corporate Social Responsibility
    • Cipla Foundation
    • CSR Policy
    • CSR Committee
    • Approved CSR Projects
      • 2022-23
      • 2021-22
  • Contact Us
  • Global
    • Brazil
    • Kenya
    • South Africa
    • Sri Lanka
    • Uganda
    • United Kingdom
    • USA

Breadcrumb

  • Home
  • Media centre
  • Media releases

Media Releases

Quick Explore

  • In the news
Media Releases 2023
Cipla certified as a Great Place to Work for the fifth year in a row
Cipla launches Cippoint – a point-of-care device for Non-Communicable Diseases, infectious diseases, and other health conditions

Corporate Information

  • About Us
  • Board of Directors
  • Code of Conduct
  • Committees of the Board
  • Management Council
  • Sustainability
  • Manufacturing
  • Milestones and Awards
  • Our Credo
  • Our History - Cipla Archives
  • Quality

Our Presence

  • Our Presence
  • Australia
  • Brazil
  • Europe
  • Kenya
  • Malaysia
  • Morocco
  • Nepal
  • South Africa
  • Spain
  • Sri Lanka
  • Uganda
  • United Kingdom
  • USA

Our Offerings

  • Our Therapies
  • Respiratory
  • Asthma
  • Paediatric Asthma
  • COPD
  • Nebulization
  • HIV/AIDS
  • Oncology
  • Cipla Generics
  • Our Offerings
  • OTC – Cipla Health
  • Cipla Diagnostics
  • API

Media

  • Media Center
  • Media Releases
  • In the News

Investor Information

  • Investors
  • Quarterly Results
  • Investor Presentation
  • Annual Reports
  • Corporate Governance
  • Disclosure under regulation 46 of SEBI
  • At a Glance
  • Board Of Directors
  • Committees of the Board
  • Investor Resources
  • Shareholding Pattern
  • Intimation to stock Exchanges
  • Unclaimed Data
  • Investor Contact
  • Disclaimer

Corporate Social Responsibility

  • CSR-Cipla Foundation
  • CSR Policy
  • CSR Committee
  • Approved CSR Projects
  • - 2022-23
  • - 2021-22

Career Sitemap

  • Careers
  • Culture and Values
  • Life at Cipla

Quick Links - Footer

  • Privacy Policy
  • Disclaimer
  • Contact Us
  • Sitemap
  • Caution Notice - Recruitment Fraud
  • Drug Safety Reporting

Related Links

  • breathefree.com
  • ciplamed.com
  • Remdesivir Supply Details - Maharashtra

© Copyright 2019 Cipla Inc. All rights reserved

  •  
  •  
  •  
  •  
  •  

Subscribe to Cipla Newsletter

  •  
  •  
  •  
  •  

Mobile Footer Menu

  • Remdesivir Supply Details - Maharashtra
  • Caution Notice - "Recruitment Fraud"
  • Contact Us
  • Disclaimer
  • Privacy Policy

© Copyright 2019 Cipla Inc. All rights reserved

×